Poly Medicure Q2 FY27 Results: Revenue ₹508.71 Crore, Net Profit ₹92.03 Crore
Poly Medicure reported Q2 FY27 standalone revenue of ₹508.71 crore and net profit of ₹92.03 crore. Consolidated revenue was ₹599.53 crore with a net profit of ₹95.13 crore. For the half-year, standalone revenue was ₹968.45 crore (net profit ₹180.15 crore) and consolidated revenue was ₹1,158.31 crore (net profit ₹180.40 crore).
The financial results are material for investors and stakeholders, impacting the company's valuation and investment decisions. The increase in revenue and profit positively influences market perception.
The company reported increased revenue and net profit for the quarter and half-year compared to the previous year, indicating positive financial performance.
Poly Medicure Limited announced its unaudited financial results for the second quarter and half-year ended September 30, 2026.
For the quarter ended September 30, 2026, the company reported a total income from operations of ₹50,871.28 lakhs (₹508.71 crore) on a standalone basis. The net profit after tax for the quarter stood at ₹9,202.50 lakhs (₹92.03 crore). On a consolidated basis, total income from operations was ₹59,953.49 lakhs (₹599.53 crore) and the net profit after tax was ₹9,512.58 lakhs (₹95.13 crore).
For the half-year ended September 30, 2026, the standalone total income from operations was ₹96,844.87 lakhs (₹968.45 crore), with a net profit after tax of ₹18,014.83 lakhs (₹180.15 crore). The consolidated total income from operations for the half-year was ₹1,15,830.62 lakhs (₹1,158.31 crore), and the net profit after tax was ₹18,040.01 lakhs (₹180.40 crore).
The company also published newspaper advertisements in the Financial Express and Jansatta on November 06, 2026, detailing these financial results.
What to do with a filing like this
Poly Medicure Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Poly Medicure Limited. Read the original for the full detail.